Epitope mapping of monoclonal antibodies: a comprehensive comparison of different technologies

References

• Grilo AL, Mantalaris A. The increasingly human and profitable monoclonal antibody market. Trends Biotechnol. 2019;37(1):9–12. doi:10.1016/j.tibtech.2018.05.014.
   PubMed Web of Science ®Google Scholar
• Mullard A. FDA approves 100th monoclonal antibody product. Nat Rev Drug Discov. 2021;20(7):491–95. doi:10.1038/d41573-021-00079-7.
   PubMed Web of Science ®Google Scholar
• Sukumar S, Wilson DC, Yu Y, Wong J, Naravula S, Ermakov G, Riener R, Bhagwat B, Necheva AS, Grein J, et al. Characterization of MK-4166, a clinical agonistic antibody that targets human GITR and inhibits the generation and suppressive effects of T regulatory cells. Cancer Res. 2017;77(16):4378–88. 1439.2016. doi:10.1158/0008-5472.CAN-16-1439.
   PubMed Web of Science ®Google Scholar
• van Meerten T, Rozemuller H, Hol S, Moerer P, Zwart M, Hagenbeek A, Mackus WJM, Parren PWHI, van de Winkel JGJ, Ebeling SB, et al. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20low expressing tumor cells that resist Rituximab mediated lysis. Haematologica. 2010;95(12):2063–71. haematol.2010.025783. doi:10.3324/haematol.2010.025783.
   PubMed Web of Science ®Google Scholar
• He W, Tan GS, Mullarkey CE, Lee AJ, Lam MMW, Krammer F, Henry C, Wilson PC, Ashkar AA, Palese P, et al. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc Natl Acad Sci USA. 2016;113(42):11931. doi:10.1073/pnas.1609316113.
   PubMed Web of Science ®Google Scholar
• de Goeij BECG, Peipp M, de Haij S, van den Brink EN, Kellner C, Riedl T, de Jong R, Vink T, Strumane K, Bleeker WK, et al. HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design. MAbs. 2014;6(2):392–402. doi:10.4161/mabs.27705.
   PubMed Web of Science ®Google Scholar
• Deng X, Storz U, Doranz BJ. Enhancing antibody patent protection using epitope mapping information. MAbs. 2018;10(2):204–09. doi:10.1080/19420862.2017.1402998.
   PubMed Web of Science ®Google Scholar
• Acchione M, Lipschultz CA, DeSantis ME, Shanmuganathan A, Li M, Wlodawer A, Tarasov S, Smith-Gill SJ. Light chain somatic mutations change thermodynamics of binding and water coordination in the HyHEL-10 family of antibodies. Mol Immunol. 2009;47(2–3):457–64. doi:10.1016/j.molimm.2009.08.018.
   PubMed Web of Science ®Google Scholar
• Gribenko AV, Parris K, Mosyak L, Li S, Handke L, Hawkins JC, Severina E, Matsuka YV, Anderson AS. High resolution mapping of bactericidal monoclonal antibody binding epitopes on Staphylococcus aureus antigen MntC. PLoS Pathog. 2016;12(9):e1005908. doi:10.1371/journal.ppat.1005908.
   PubMed Web of Science ®Google Scholar
• Garman EF. Developments in X-ray crystallographic structure determination of biological macromolecules. Sci. 2014;343(6175):1102. doi:10.1126/science.1247829.
   PubMed Web of Science ®Google Scholar
• Zhang M, Huang R, Beno B, Deyanova E, Li J, Chen G, Gross M. Epitope and paratope mapping of PD-1/Nivolumab by mass spectrometry-based Hydrogen–deuterium exchange, cross-linking, and molecular docking. Anal Chem. 2020;92(13):9086–94. doi:10.1021/acs.analchem.0c01291.
   PubMed Web of Science ®Google Scholar
• Abbott WM, Damschroder MM, Lowe DC. Current approaches to fine mapping of antigen–antibody interactions. Immunology. 2014;142(4):526–35. doi:10.1111/imm.12284.
   PubMed Web of Science ®Google Scholar
• Liu X, Huang R, Zhao F, Chen G, Tao L. Advances in mass spectrometry-based epitope mapping of protein therapeutics. J Pharmaceut Biomed. 2022;215:114754. doi:10.1016/j.jpba.2022.114754.
   PubMed Web of Science ®Google Scholar
• Leitner A. Cross-linking and other structural proteomics techniques: how chemistry is enabling mass spectrometry applications in structural biology. Chem Sci. 2016;7(8):4792–803. doi:10.1039/C5SC04196A.
   PubMed Web of Science ®Google Scholar
• Lee JY, Lee HT, Shin W, Chae J, Choi J, Kim SH, Lim H, Won Heo T, Park KY, Lee YJ, et al. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat Commun. 2016;7(1):13354. doi:10.1038/ncomms13354.
   PubMedGoogle Scholar
• Ramagopal UA, Liu W, Garrett-Thomson SC, Bonanno JB, Yan Q, Srinivasan M, Wong SC, Bell A, Mankikar S, Rangan VS, et al. Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab. Proc Natl Acad Sci USA. 2017;114(21):E4223. doi:10.1073/pnas.1617941114.
   PubMed Web of Science ®Google Scholar
• Bai A, Meetze K, Vo N, Kollipara S, Mazsa E, Winston W, Weiler S, Poling L, Chen T, Ismail N, et al. GP369, an FGFR2-IIIb–Specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res. 2010;70(19):7630–39. doi:10.1158/0008-5472.CAN-10-1489.
   PubMed Web of Science ®Google Scholar
• Wang C, Thudium K, Han M, Wang X, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2(9):846–56. doi:10.1158/2326-6066.CIR-14-0040.
   PubMed Web of Science ®Google Scholar
• Guadagnoli M, Kimberley FC, Phan U, Cameron K, Vink PM, Rodermond H, Eldering E, Kater AP, van Eenennaam H, Medema JP, et al. Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. Blood. 2011;117(25):6856–65. doi:10.1182/blood-2011-01-330852.
   PubMed Web of Science ®Google Scholar
• https://nationalmaglab.org/user-facilities/icr/techniques/hd-exchange.
   Google Scholar
• Alverdi V, Mazon H, Versluis C, Hemrika W, Esposito G, van den Heuvel R, Scholten A, Heck AJR. cGMP-binding prepares PKG for substrate binding by disclosing the C-terminal domain. J Mol Biol. 2008;375(5):1380–93. doi:10.1016/j.jmb.2007.11.053.
   PubMed Web of Science ®Google Scholar
• Huang W, Ravikumar K, Chance M, Mark R, Yang S. Quantitative mapping of protein structure by hydroxyl radical footprinting-mediated Structural mass spectrometry: a protection factor analysis. Biophys J. 2015;108(1):107–15. doi:10.1016/j.bpj.2014.11.013.
   PubMed Web of Science ®Google Scholar
• Maleknia SD, Downard KM. Radical approaches to probe protein structure, folding, and interactions by mass spectrometry. Mass Spectrom Rev. 2001;20(6):388–401. doi:10.1002/mas.10013.
   PubMed Web of Science ®Google Scholar
• Merkley ED, Rysavy S, Kahraman A, Hafen RP, Daggett V, Adkins JN. Distance restraints from crosslinking mass spectrometry: mining a molecular dynamics simulation database to evaluate lysine–lysine distances. Protein Sci. 2014;23(6):747–59. doi:10.1002/pro.2458.
   PubMed Web of Science ®Google Scholar
• Rand KD, Zehl M, Jørgensen TJD. Measuring the Hydrogen/Deuterium Exchange of Proteins at High Spatial Resolution by Mass Spectrometry: Overcoming Gas-Phase Hydrogen/Deuterium Scrambling. Acc Chem Res. 2014;47(10):3018–27. doi:10.1021/ar500194w.
   PubMed Web of Science ®Google Scholar
• Hamuro Y, E SY. Determination of backbone amide hydrogen exchange rates of cytochrome c using partially scrambled electron transfer dissociation data. J Am Soc Mass Spectrom. 2018;29(5):989–1001. doi:10.1007/s13361-018-1892-3.
   PubMed Web of Science ®Google Scholar
• Brodie NI, Huguet R, Zhang T, Viner R, Zabrouskov V, Pan J, Petrotchenko EV, Borchers CH. Top-down Hydrogen–deuterium exchange analysis of protein structures using ultraviolet photodissociation. Anal Chem. 2018;90(5):3079–82. doi:10.1021/acs.analchem.7b03655.
   PubMed Web of Science ®Google Scholar
• Schmitz C, Melquiond AS, de Vries SJ, Karaca E, van Dijk M, Kastritis PL, Bonvin AM. Protein–Protein Docking with HADDOCK. NMR Of Biomolecules. 2012;520–535. doi:10.1002/9783527644506.ch32.
   Google Scholar
• Zhang Y, Rempel DL, Zhang H, Gross ML. An improved fast photochemical oxidation of proteins (FPOP) platform for protein therapeutics. J Am Soc Mass Spectrom. 2015;26(3):526–29. doi:10.1007/s13361-014-1055-0.
   PubMed Web of Science ®Google Scholar
• Chance MR, Farquhar ER, Yang S, Lodowski DT, Kiselar J. Protein footprinting: auxiliary engine to power the Structural biology revolution. J Mol Biol. 2020;432(9):2973–84. doi:10.1016/j.jmb.2020.02.011.
   PubMed Web of Science ®Google Scholar
• Meyerson JR, Kumar J, Chittori S, Rao P, Pierson J, Bartesaghi A, Mayer ML, Subramaniam S. Structural mechanism of glutamate receptor activation and desensitization. Nature. 2014;514(7522):328. https://www.nature.com/articles/nature13603#supplementary-information.
   PubMed Web of Science ®Google Scholar
• Bardelli M, Livoti E, Simonelli L, Pedotti M, Moraes A, Valente AP, Varani L. Epitope mapping by solution NMR spectroscopy. J Of Molecular Recognition. 2015;28(6):393–400. doi:10.1002/jmr.2454.
   PubMed Web of Science ®Google Scholar
• Monaco S, Tailford LE, Juge N, Angulo J. Differential epitope mapping by STD NMR spectroscopy to reveal the nature of protein–ligand contacts. Angew Chem Int Ed. 2017;56(48):15289–93. doi:10.1002/anie.201707682.
   PubMed Web of Science ®Google Scholar
• Renaud J-P, Chari A, Ciferri C, Liu W-T, Rémigy H-W, Stark H, Wiesmann C. Cryo-EM in drug discovery: achievements, limitations and prospects. Nat Rev Drug Discov. 2018;17(7):471–92. doi:10.1038/nrd.2018.77.
   PubMed Web of Science ®Google Scholar
• Götze M, Pettelkau J, Schaks S, Bosse K, Ihling CH, Krauth F, Fritzsche R, Kühn U, Sinz A. StavroX—A software for analyzing crosslinked products in protein interaction studies. J Am Soc Mass Spectrom. 2012 Jan;23(1):76–87. doi:10.1007/s13361-011-0261-2.
   PubMed Web of Science ®Google Scholar